Thymalin 10mg (with Bacteriostatic Water)

Thymalin is a peptide preparation extracted from calf (bovine) thymus, developed and characterized principally in Russian/Soviet immunology and gerontology research beginning in the 1970s by Vladimir Khavinson, Vyacheslav Morozov, and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg. The preparation is a mixture of short peptides (predominantly di-, tri-, and tetra-peptides) isolated from acid-extracted bovine thymus tissue, with the peptide mixture characterized in the historical research literature as having immunomodulatory activity in models of immune dysfunction and as having gerontological-research interest in age-related immune decline.

Thymalin is distinguished from the structurally defined synthetic thymic peptides that have emerged from related research lines — including thymosin alpha-1 (a 28-amino-acid synthetic peptide developed and approved as Zadaxin in some jurisdictions for specific indications) and thymopentin (a synthetic pentapeptide corresponding to a region of thymopoietin). Thymalin is a tissue-extract peptide preparation rather than a single defined peptide molecule; the composition is characterized by the extraction methodology rather than by a single primary sequence. The related compound thymogen (a synthetic dipeptide Glu-Trp characterized in the same Russian research program) is a defined-structure synthetic short peptide derived from the analytical fractionation of the thymalin extract.

This page is a research-only educational reference for Thymalin as a research-supply preparation. The molecule has historical regulatory status in some Eastern-European and post-Soviet jurisdictions but is not approved as a medicine by the US FDA, the EMA, or major Western regulatory authorities. No medical or therapeutic claims are made on this page, and the educational content is provided for research-context understanding of the historical literature and the broader thymic-peptide research landscape.

Thymalin is a peptide-containing extract prepared from calf (bovine) thymus tissue by acid extraction and subsequent purification through precipitation and chromatographic separation. The preparation is characterized as a complex mixture of short peptides (predominantly di-, tri-, and tetra-peptides) with some larger peptide and polypeptide components. The specific composition depends on the extraction methodology and on the source tissue; characterization studies of Thymalin in the historical research literature describe the peptide-fragment profile of the preparation rather than identifying a single defined primary sequence as the active component.

The Russian/Soviet research program in thymic peptides was initiated in the 1960s and 1970s in the context of immunology and gerontology research investigating the role of the thymus in immune system development and in age-related immune decline (immunosenescence). The thymus is the central primary lymphoid organ responsible for T-cell development; thymic involution (progressive size and functional reduction of the thymus from puberty onward) is a hallmark of aging biology and is implicated in age-related decline in adaptive immune competence. The hypothesis that thymic-derived peptide signals could be characterized and used pharmacologically motivated the extraction and characterization of thymic-tissue peptide preparations across multiple research lines internationally.

The Khavinson laboratory at the Institute of Bioregulation and Gerontology in St. Petersburg has been the principal source of Thymalin research literature. Khavinson and colleagues have published extensively on Thymalin in animal models of immune dysfunction, in models of age-related immune decline, and in human-research contexts in Russia. The preparation has historical regulatory status in Russia and some post-Soviet jurisdictions; the regulatory framework for tissue-extract peptide preparations differs substantially between jurisdictions, and the molecule is not approved by Western regulatory authorities.

Analytical fractionation of the Thymalin extract by the same research group identified a synthetic dipeptide Glu-Trp (glutamyl-tryptophan) — subsequently named thymogen — as a defined-structure short peptide with biological activity in immunomodulatory assays. Thymogen has been characterized as a single-molecule research compound in its own right and is sometimes distinguished from Thymalin (the extract preparation) in the published literature. The relationship between the Thymalin extract and thymogen is that thymogen represents one well-characterized component of the broader peptide-mixture extract, but the biological activity of Thymalin as a whole is attributed in the historical research literature to multiple peptide components acting collectively.

The Russian research line on Thymalin and thymogen is part of a broader research program in "regulatory peptides" (the term used by the Khavinson group) — a category of short bioactive peptides derived from various tissues (thymus, pineal gland, retina, prostate, others) and characterized as proposed tissue-specific bioregulators in age-related and functional contexts. The other principal regulatory peptide from this research program is epitalon (Ala-Glu-Asp-Gly), derived from pineal-gland tissue; epitalon is characterized in the same body of literature and has its own product page in this catalog. The Khavinson regulatory-peptide research program is a distinctive research line with its own historical context, methodology, and publication record.

It is important to be clear about what Thymalin is not. It is not thymosin alpha-1 — that is a separate, structurally defined 28-amino-acid synthetic peptide developed by SciClone Pharmaceuticals and others, approved in some jurisdictions for specific clinical indications (e.g., hepatitis B in Italy and other countries). It is not thymopentin — that is a synthetic pentapeptide corresponding to a region of thymopoietin, separately characterized. It is not an approved medicine by the FDA, EMA, or other major Western regulatory authorities. And it is not a defined single peptide molecule — it is a tissue-extract preparation characterized by its extraction methodology and peptide-fragment profile.

Research on thymic peptide preparations originated in the 1960s with the recognition of the thymus as the central primary lymphoid organ for T-cell development and the hypothesis that thymic-derived humoral factors could mediate aspects of immune function beyond the cellular-trafficking role of the organ itself. Multiple international research lines developed thymic-peptide preparations and synthetic thymic peptides through the 1960s, 1970s, and 1980s.

The Western thymic-peptide research line was led by Allan Goldstein at George Washington University and colleagues with the characterization of thymosin (a thymic-tissue extract preparation analogous in some respects to Thymalin) and subsequent identification of thymosin alpha-1 (a 28-amino-acid synthetic peptide derived from one component of the thymosin extract). Thymosin alpha-1 was subsequently developed clinically by SciClone Pharmaceuticals and others and approved in some jurisdictions for specific indications including hepatitis B and as an adjunct in certain oncology contexts. The Goldstein research program also characterized thymosin alpha-1 in immunology research and in models of immune dysfunction.

The Russian/Soviet thymic-peptide research line was led by Vyacheslav Morozov, Vladimir Khavinson, and colleagues at what is now the Institute of Bioregulation and Gerontology in St. Petersburg. This research line characterized Thymalin (the bovine thymus extract preparation), thymogen (the synthetic dipeptide Glu-Trp identified by fractionation of Thymalin), and a broader portfolio of "regulatory peptides" from various tissues (thymus, pineal, retina, prostate, others). The research methodology and publication record of the Khavinson group is extensive but is concentrated in Russian-language journals and conferences, with English-language summaries and translated reports providing the principal access for Western readers. The historical context of the research includes the Soviet-era biological-research infrastructure and the specific gerontological focus that distinguished the Khavinson program from Western thymic-peptide research.

The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr; corresponding to residues 32-36 of the thymic hormone thymopoietin) was developed by a separate research line in the 1970s and characterized in Western immunology research; it is structurally and historically distinct from both Thymalin and from the thymosin family.

Thymalin received regulatory approval in Russia in the 1970s and has historical use as a registered immunomodulatory preparation in Russia and some post-Soviet jurisdictions; the specific regulatory framework, indication labels, and clinical-use context in those jurisdictions differ from Western pharmaceutical regulation and from the research-supply context of this educational reference. The molecule is not approved by the US FDA, the EMA, or other major Western regulatory authorities, and it is not part of the Western pharmaceutical research-and-development landscape in the same way as thymosin alpha-1.

The contemporary research interest in Thymalin and the Khavinson regulatory-peptide program has continued in the geriatrics and gerontology literature, with publications investigating age-related immune-function endpoints in animal models and small human-research cohorts. The methodological standards and publication practices of this research line are distinct from the standards of modern Western clinical research, and the published evidence base should be evaluated in that context. The research-supply context of this educational reference is academic and historical-literature understanding of the thymic-peptide research field.

The thymus is the central primary lymphoid organ responsible for T-cell development. Thymopoiesis — the process by which bone-marrow-derived lymphoid progenitors enter the thymus and undergo a complex maturation program involving rearrangement of the T-cell receptor genes, positive and negative selection on thymic epithelial cells and dendritic cells, and emigration to the periphery as mature naïve T cells — is essential for the development of the adaptive immune repertoire. Thymic function is maximal in early life and declines progressively from puberty onward through a process of thymic involution, with corresponding decline in naïve T-cell output and contribution to age-related changes in adaptive immune competence.

Thymic-derived humoral factors have been hypothesized since the 1960s as potential mediators of thymic function beyond the cellular-trafficking role of the organ. Multiple thymic-peptide preparations and synthetic thymic peptides have been characterized in this research context, including thymosin (a thymic-tissue extract), thymosin alpha-1 (a 28-amino-acid synthetic peptide derived from one component of thymosin), thymopentin (a synthetic pentapeptide corresponding to a region of thymopoietin), Thymalin (the Russian bovine thymus extract preparation), and thymogen (a synthetic dipeptide derived from analytical fractionation of Thymalin). Each preparation has its own characterization literature and proposed pharmacological profile.

Thymalin is hypothesized in the historical Russian research literature to act as an immunomodulator with effects on T-cell maturation, on lymphocyte subset proportions in peripheral blood (CD4/CD8 ratios, naïve/memory T-cell distributions), and on functional immune endpoints in models of immune dysfunction. The proposed mechanisms include direct effects on thymic-epithelial-cell function, effects on T-cell maturation kinetics, and downstream effects on peripheral immune competence. The receptor target or molecular mechanism of action of specific Thymalin peptide components is less well-characterized than for the structurally defined synthetic thymic peptides like thymosin alpha-1.

In the gerontological-research context, Thymalin and related Khavinson "regulatory peptides" are hypothesized to modulate age-related immune decline and to support immune-system parameters in aged subjects. The published research from the Khavinson group includes long-term studies in animal models (with reported effects on lifespan, on tumor incidence, and on age-related disease parameters) and in human-research cohorts (with reported effects on immune-cell parameters and on age-related health endpoints). The methodology and reporting standards of this research literature differ from contemporary Western clinical-research practices, and the published evidence should be evaluated in its historical and methodological context.

The contemporary thymic-peptide research landscape includes ongoing investigation of thymosin alpha-1 in defined clinical-research contexts (sepsis, hepatitis, oncology adjunct), ongoing characterization of thymic-stromal-cell biology and thymic-regeneration approaches in the broader immunology research community, and continuing publications from the Khavinson research line on the Russian regulatory-peptide program. Western pharmaceutical interest in thymic peptide preparations is principally concentrated on defined-structure synthetic peptides (thymosin alpha-1) rather than on tissue-extract preparations like Thymalin.

Distinguishing Thymalin from related areas: the preparation is a tissue-extract peptide mixture, not a single defined molecule; it is principally characterized in Russian-language and translated literature, distinct from the Western thymosin alpha-1 research line; and it is mechanistically and structurally distinct from defined synthetic thymic peptides like thymopentin and thymosin alpha-1.

Thymalin is a tissue-extract peptide preparation rather than a single defined chemical entity. The preparation is characterized as a complex mixture of short peptides (predominantly di-, tri-, and tetra-peptides) extracted from calf (bovine) thymus by acid extraction and subsequent purification through precipitation and chromatographic separation. The specific composition of the preparation depends on the extraction methodology and the source tissue; analytical characterization studies in the historical research literature describe the peptide-fragment profile of the preparation, with multiple components contributing to the overall peptide mixture.

One specific component of the Thymalin extract that has been characterized as a defined-structure molecule is the dipeptide Glu-Trp (glutamyl-tryptophan), subsequently named thymogen. Thymogen is the synthetic equivalent of this Thymalin component and is characterized as a distinct research compound with its own publication record. Other components of the Thymalin extract include longer peptides and polypeptide fragments derived from thymic tissue proteins; the overall composition is not fully characterized to a single-molecule level.

The molecular weight distribution of the Thymalin peptide mixture is in the low-molecular-weight range (predominantly below 1000 g/mol per component, with the synthetic dipeptide Glu-Trp at 333 g/mol as one well-characterized example). The preparation is supplied as a sterile lyophilized powder, originally formulated in the Russian regulatory framework as an injectable preparation with specific composition and stability characteristics defined by the source manufacturer.

Research-supply Thymalin is supplied as a sterile lyophilized peptide mixture in sealed vials. Lyophilized storage is at -20 °C or below in moisture-protected containers; reconstituted solutions in aqueous diluent are stored refrigerated and used within a short window per standard peptide-mixture-stability practice. The precise composition and storage specifications depend on the specific source preparation; the research-supply context is academic and laboratory use, not the historical Russian-pharmacy registered-medicine preparation.

In the published research literature, Thymalin has been investigated in several principal application areas:

Animal-model immunology research. Mouse and rat models of immune dysfunction, including aged rodent cohorts and rodents with experimentally induced immune deficiency, have been used to evaluate Thymalin administration with reports of effects on T-cell subset proportions, on lymphocyte proliferative responses, and on functional immune endpoints. The bulk of the published animal-research literature is from the Khavinson laboratory and collaborating Russian groups.

Gerontology and aging research. The Khavinson research program has used Thymalin and related regulatory peptides in long-term rodent studies investigating lifespan, age-related disease incidence, and age-associated functional endpoints. The methodology and reporting practices of these studies differ from contemporary Western standards and should be evaluated in their historical context.

Human-research cohorts in Russian/post-Soviet jurisdictions. Thymalin has been used in human-research cohorts in Russia and some post-Soviet jurisdictions in the context of its historical regulatory approval in those jurisdictions. The published reports include immunological endpoints (lymphocyte subset measurements, immune-function tests) and clinical endpoints in specific patient populations. These reports represent historical clinical-research and registered-medicine use in the relevant jurisdictions; the research-supply context of this page is academic understanding of this literature, not endorsement of the historical clinical-use contexts.

Comparative thymic-peptide research. Thymalin is referenced in the broader thymic-peptide research literature alongside thymosin alpha-1, thymopentin, and other thymic-peptide preparations and synthetic compounds. Comparative immunology and thymic-biology studies have referenced the Russian thymic-peptide research line as part of the international historical context of thymic-peptide pharmacology.

Mechanism-of-action research. Analytical fractionation of Thymalin and characterization of specific peptide components (notably the dipeptide Glu-Trp / thymogen) has been used in research investigating the molecular basis of the proposed immunomodulatory activity of the extract preparation.

All applications described on this page are research-supply context for academic and historical-literature understanding of the thymic-peptide research field. The molecule is not for human consumption in the research-supply context; the historical Russian/post-Soviet clinical-use contexts are separate and governed by the relevant national regulatory frameworks, which differ substantially from Western pharmaceutical regulation. Nothing on this page describes a clinical protocol or therapeutic recommendation.

Thymalin sits within the broader thymic-peptide research landscape alongside Western synthetic thymic peptides and other thymic-derived preparations.

Thymalin is a peptide preparation extracted from calf (bovine) thymus, developed and characterized in Russian/Soviet immunology and gerontology research beginning in the 1970s by Khavinson, Morozov, and colleagues at what is now the Institute of Bioregulation and Gerontology in St. Petersburg. The preparation is a complex mixture of short peptides (predominantly di-, tri-, and tetra-peptides) characterized in the historical research literature as having immunomodulatory activity in models of immune dysfunction and gerontological-research interest in age-related immune decline. The dipeptide Glu-Trp (subsequently named thymogen) is one well-characterized component identified through analytical fractionation of the extract.

Thymalin is distinguished from the structurally defined Western synthetic thymic peptides — thymosin alpha-1 (the 28-amino-acid synthetic peptide developed in the Goldstein research line and approved as Zadaxin in some jurisdictions for specific clinical indications), thymopentin (the synthetic pentapeptide corresponding to a region of thymopoietin), and others. Thymalin is a tissue-extract preparation, not a single defined molecule, and is from a distinct research-program origin.

This page is research educational only. Thymalin has historical regulatory status in Russia and some post-Soviet jurisdictions but is NOT approved by the US FDA, the European Medicines Agency, or other major Western regulatory authorities. Research-supply Thymalin is supplied for academic and laboratory understanding of the historical thymic-peptide research literature; no medical or therapeutic claims are made.